1. CTRP6 is an endogenous complement regulator that can effectively treat induced arthritis.
- Author
-
Murayama MA, Kakuta S, Inoue A, Umeda N, Yonezawa T, Maruhashi T, Tateishi K, Ishigame H, Yabe R, Ikeda S, Seno A, Chi HH, Hashiguchi Y, Kurata R, Tada T, Kubo S, Sato N, Liu Y, Hattori M, Saijo S, Matsushita M, Fujita T, Sumida T, and Iwakura Y
- Subjects
- Adipokines genetics, Adult, Animals, Arthritis, Experimental genetics, Arthritis, Experimental pathology, Arthritis, Rheumatoid genetics, Arthritis, Rheumatoid pathology, Arthus Reaction genetics, Arthus Reaction immunology, Arthus Reaction metabolism, Blotting, Western, Collagen immunology, Collagen metabolism, Complement C3-C5 Convertases immunology, Complement C3a immunology, Complement C5a immunology, Complement Pathway, Alternative genetics, Disease Models, Animal, Encephalomyelitis, Autoimmune, Experimental genetics, Encephalomyelitis, Autoimmune, Experimental immunology, Encephalomyelitis, Autoimmune, Experimental metabolism, Female, Flow Cytometry, Humans, Immunoprecipitation, Macrophages immunology, Male, Mice, Mice, Knockout, Mice, Transgenic, Middle Aged, Real-Time Polymerase Chain Reaction, Reverse Transcriptase Polymerase Chain Reaction, Synovial Membrane cytology, Synovial Membrane metabolism, Adipokines immunology, Arthritis, Experimental immunology, Arthritis, Rheumatoid immunology, Complement Pathway, Alternative immunology
- Abstract
The complement system is important for the host defence against infection as well as for the development of inflammatory diseases. Here we show that C1q/TNF-related protein 6 (CTRP6; gene symbol C1qtnf6) expression is elevated in mouse rheumatoid arthritis (RA) models. C1qtnf6(-/-) mice are highly susceptible to induced arthritis due to enhanced complement activation, whereas C1qtnf6-transgenic mice are refractory. The Arthus reaction and the development of experimental autoimmune encephalomyelitis are also enhanced in C1qtnf6(-/-) mice and C1qtnf6(-/-) embryos are semi-lethal. We find that CTRP6 specifically suppresses the alternative pathway of the complement system by competing with factor B for C3(H2O) binding. Furthermore, treatment of arthritis-induced mice with intra-articular injection of recombinant human CTRP6 cures the arthritis. CTRP6 is expressed in human synoviocytes, and CTRP6 levels are increased in RA patients. These results indicate that CTRP6 is an endogenous complement regulator and could be used for the treatment of complement-mediated diseases.
- Published
- 2015
- Full Text
- View/download PDF